A4 Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

A4 Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Buy	+471	New	+$209K	0.16%	81

Other funds holding VRTX

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

A4 Wealth Advisors's VRTX Position: Q2 2026 in Review

A4 Wealth Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 471 shares worth $234K. The stake represents 0.16% of the portfolio and ranks #81 among its holdings.

947 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

A4 Wealth Advisors held 471 shares of Vertex Pharmaceuticals worth $234K as of Q2 2026.
Vertex Pharmaceuticals was a new A4 Wealth Advisors position in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of A4 Wealth Advisors's portfolio in Q2 2026, its #81 holding.
947 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on A4 Wealth Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.